Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
European Journal of Clinical Pharmacology|April 7, 2009
Evaluation of drug-drug interactions with fesoterodineBimal Malhotra, Richard Sachse, Nolan WoodAntimicrobial Agents and Chemotherapy|August 31, 2011
Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential useBharat Damle, Manthena V Varma, Nolan WoodJournal of Aerosol Medicine and Pulmonary Drug Delivery|August 1, 2019
Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence StudiesScott Haughie, Richard Allan, Nolan Wood, et al.British Journal of Clinical Pharmacology|November 18, 2003
Voriconazole potentiates warfarin-induced prothrombin time prolongationLynn Purkins, Nolan Wood, Diane Kleinermans, et al.Journal of Clinical Pharmacology|February 28, 2009
Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodineBimal Malhotra, Kuan Gandelman, Richard Sachse, et al.British Journal of Clinical Pharmacology|November 18, 2003
Voriconazole does not affect the steady-state pharmacokinetics of digoxinLynn Purkins, Nolan Wood, Diane Kleinermans, et al.British Journal of Clinical Pharmacology|November 18, 2003
Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazoleLynn Purkins, Nolan Wood, Diane Kleinermans, et al.British Journal of Clinical Pharmacology|November 18, 2003
No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteersLynn Purkins, Nolan Wood, Diane Kleinermans, et al.British Journal of Clinical Pharmacology|November 18, 2003
Effect of food on the pharmacokinetics of multiple-dose oral voriconazoleLynn Purkins, Nolan Wood, Diane Kleinermans, et al.Journal of Clinical Pharmacology|January 25, 2006
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalitiesKeith Tan, Nigel Brayshaw, Konrad Tomaszewski, et al.Pageof 2